作者: Amr A. Abdeen , Krishanu Saha
DOI: 10.1016/J.TIBTECH.2017.06.008
关键词:
摘要: Emerging manufacturing processes to generate regenerative advanced therapies can involve extensive genomic and/or epigenomic manipulation of autologous or allogeneic cells. These cell engineering need be carefully controlled and standardized maximize safety efficacy in clinical trials. Engineered biomaterials with smart tunable properties offer an intriguing tool provide deliver cues retain stemness, direct differentiation, promote reprogramming, manipulate the genome, select functional phenotypes. This review discusses use engineered control human manufacturing. Future work exploiting has potential that produce cells well-defined critical quality attributes appropriate for testing.